A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and establish the maximum tolerated dose
(MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion
in patients with advanced solid tumors.